Brief: Ascelia Pharma Signs Clinical Collaboration Agreement With Taiho Oncology

Ascelia Pharma AB

21/09/2021 06:33

Sept 21 (Reuters) - Ascelia Pharma AB  ACELP.ST :
    * ASCELIA PHARMA SIGNS CLINICAL COLLABORATION AGREEMENT WITH
TAIHO
ONCOLOGY, INC. FOR THE DEVELOPMENT OF ONCORAL IN COMBINATION
WITH LONSURF®
    * AS PART OF AGREEMENT, TAIHO ONCOLOGY WILL SUPPLY LONSURF
AS WELL
AS PROVIDE SCIENTIFIC EXPERTISE FOR STUDY
    * DEPENDING ON RESULTS, COLLABORATION MAY BE EXTENDED FOR
FURTHER
DEVELOPMENT OF TWO AGENTS
    * ASCELIA PHARMA RETAINS FULL DEVELOPMENT AND
COMMERCIALIZATION
RIGHTS TO ONCORAL
    * STUDY IS PLANNED TO START IN H2 2021 AND WILL INCLUDE
APPROXIMATELY 100 PATIENTS WITH METASTATIC GASTRIC CANCER
    * PRIMARY ENDPOINT WILL BE PROGRESSION-FREE SURVIVAL, WITH
SECONDARY ENDPOINTS INCLUDING RESPONSE RATE, OVERALL SURVIVAL,
PHARMACOKINETICS, SAFETY, AND TOLERABILITY
    * INITIAL PORTION OF PLANNED GLOBAL STUDY WILL BE CONDUCTED
AT
HOSPITALS AND CLINICS IN EUROPE

Source text for Eikon:  ID:nMFN7ygX06 
Further company coverage:  ACELP.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 6600;))